5X2K

Crystal structure of EGFR 696-1022 T790M in complex with WZ4003

  • Classification: TRANSFERASE
  • Organism(s): Homo sapiens
  • Expression System: Spodoptera frugiperda
  • Mutation(s): 

  • Deposited: 2017-02-01 Released: 2018-02-21 
  • Deposition Author(s): Zhu, S.J., Zhao, P., Yun, C.H.
  • Funding Organization(s): National Science Foundation of China; National Basic Research Program of China; inistry of Science and Technology of China 

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.201 Å
  • R-Value Free: 0.244 
  • R-Value Work: 0.226 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Structural insights into drug development strategy targeting EGFR T790M/C797S.

Zhu, S.J.Zhao, P.Yang, J.Ma, R.Yan, X.E.Yang, S.Y.Yang, J.W.Yun, C.H.

(2018) Oncotarget 9: 13652-13665

  • DOI: 10.18632/oncotarget.24113
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Treatment of non-small-cell lung cancers (NSCLCs) harboring primary EGFR oncogenic mutations such as L858R and exon 19 deletion delE746_A750 (Del-19) using gefitinib/erlotinib ultimately fails due to the emergence of T790M mutation. Though WZ4002/CO- ...

    Treatment of non-small-cell lung cancers (NSCLCs) harboring primary EGFR oncogenic mutations such as L858R and exon 19 deletion delE746_A750 (Del-19) using gefitinib/erlotinib ultimately fails due to the emergence of T790M mutation. Though WZ4002/CO-1686/AZD9291 are effective in overcoming EGFR T790M by targeting Cys797 via covalent bonding, their efficacy is again limited due to the emergence of C797S mutation. New agents effectively inhibiting EGFR T790M without covalent linkage through Cys 797 may solve this problem. We presented here crystal structures of EGFR activating/drug-resistant mutants in complex with a panel of reversible inhibitors along with mutagenesis and enzyme kinetic data. These data revealed a previously un-described hydrophobic clamp structure in the EGFR kinase which may be exploited to facilitate development of next generation drugs targeting EGFR T790M with or without concomitant C797S. Interestingly, mutations in the hydrophobic clamp that hinder drug binding often also weaken ATP binding and/or abolish kinase activity, thus do not readily result in resistance to the drugs.


    Organizational Affiliation

    Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Epidermal growth factor receptor
A
327Homo sapiensMutation(s): 1 
Gene Names: EGFR (ERBB, ERBB1, HER1)
EC: 2.7.10.1
Find proteins for P00533 (Homo sapiens)
Go to Gene View: EGFR
Go to UniProtKB:  P00533
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
0UN
Query on 0UN

Download SDF File 
Download CCD File 
A
N-{3-[(5-chloro-2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)oxy]phenyl}prop-2-enamide
C25 H27 Cl N6 O3
ITTRLTNMFYIYPA-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.201 Å
  • R-Value Free: 0.244 
  • R-Value Work: 0.226 
  • Space Group: I 2 3
Unit Cell:
Length (Å)Angle (°)
a = 149.273α = 90.00
b = 149.273β = 90.00
c = 149.273γ = 90.00
Software Package:
Software NamePurpose
PHASERphasing
PHENIXrefinement
HKL-3000data scaling
HKL-3000data reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Science Foundation of ChinaChina31270769
National Basic Research Program of ChinaChina2012CB917202
inistry of Science and Technology of ChinaChina--

Revision History 

  • Version 1.0: 2018-02-21
    Type: Initial release
  • Version 1.1: 2018-04-11
    Type: Data collection, Database references